SavedAdd your journal

Journals / Solunum / 2008 / Cilt: 10 - Sayı: 2

An important side effect of dopamine agonists: Lung fibrosis

Dopamin agonistlerinin önemli bir yan etkisi: Akciğer fibrozu

GÜLÇİN BENBİR ŞENEL
Sevtap Sipahi DEMİRKÖK
Sibel ERTAN
Journal
Solunum
Pages
147–152
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Follow-up in patients treated with ergot- dopamin agonists is therefore important by monitoring the related symptoms, and regular screening tests.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Dopamine agonists, particularly ergot preperations, are related to pulmonary or retroperitoneal fibrosis, or cardiac valvular diseases.
📊
Key Findings & Data:Several hypotheses have been suggested to explain the pathophysiological mechanism, including toxic fibrogenesis, vascular theory, and immunological theory.
💡
Conclusion & Impact:Follow-up in patients treated with ergot- dopamin agonists is therefore important by monitoring the related symptoms, and regular screening tests.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Retroperitoneal fibrozis · Dopamin agonistleri · Kalp kapağı hastalıkları

Abstract

Dopamine agonists, particularly ergot preperations, are related to pulmonary or retroperitoneal fibrosis, or cardiac valvular diseases. Several hypotheses have been suggested to explain the pathophysiological mechanism, including toxic fibrogenesis, vascular theory, and immunological theory. The fibrotic disease is said to be often reversible if the drug is stopped quickly. Follow-up in patients treated with ergot- dopamin agonists is therefore important by monitoring the related symptoms, and regular screening tests.

Özet

Özellikle ergot türevleri olmak üzere dopamin agonislerinin (DA) akciğer veya retroperitoneal fibroz, ya da kardiyak kapak hastalığı yan etkileri bildirilmektedir. Patofizyolojik mekanizmayı açıklamaya yönelik toksik fibrogenez, vasküler teori ve immünolojik teori olmak üzere birçok hipotez öne sürülmektedir. Fibrotik hastalık ilacın erken kesilmesi ile genellikle gerilemektedir. Bu nedenle, ergot türevi DA kullanan hastalarda semptomların yakın takibi ve düzenli tarama testleri oldukça faydalıdır.

🔖

Cite This Article

ŞENEL, G. B., DEMİRKÖK, S. S., ERTAN, S. (2008). An important side effect of dopamine agonists: Lung fibrosis. Solunum, Cilt: 10 - Sayı: 2, 147–152. https://ajindex.com/articles/314441

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (19)

  1. Tintner R, Jankovic J. Dopamine agonists in Parkinson's disease. 2003; 12: 1803- 20
  2. Özekmekçi S. Parkinson hastalığının erken evresinde tedaviye başlama. T Klin J Neurol 2003; 1: 188- 94
  3. Özekmekçi S. Parkinson hastalığının tedavisi. Hareket Boz Der 2001; 4: 125- 32
  4. Bhatia K, Brooks DJ, Burn DJ, et al. Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group. Hosp Med 1998; 59: 469- 80
  5. Danoff SK, GrassoME, Terry PB, Flynn JA. Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest 2001; 120: 313- 6
  6. Vergeret J, Barat M, Taytard A, et al. Pleuropulmonary fibrosis and bromocriptine. Sem Hop 1984; 8: 741- 4
  7. Bleumink GS, van der Molen-Eijgenraam M, Strijbos JH, Sanwikarja S. Pergolide induced pleuropulmonary fibrosis. Clin Neuropharmacol 2002; 25: 290- 3
  8. Goldstein M, Liebermann A, Lew JY, et al. Interaction of pergolide with central dopaminergic receptor. Proc Natl Acad Sci USA 1980; 77: 3725- 8
  9. Grandas F, Galiano ML. Pramipexol: a new dopaminergic agonist for the treatment of Parkinson disease. Neurologia 1999; 14: 224- 8
  10. No authors listed. Fibrosis due to ergot derivatives: exposure to risk should be weighed up. Prescribe Int 2002; 11: 186- 9
  11. Lang AE, Lozano AM. Parkinson’s disease second of two parts. N Engl J Med 1998; 339: 1130- 43
  12. Adams RD, Victor M, Roper AH. Principles of Neurology. International Edition (6th eds.) 1997: 1046- 107
  13. Dukes MNG. Meyler’s side effects of drugs, 13th Ed. Elsevier Science BV Amsterdam, 1996
  14. Pfitzenmeyer P, Foucher P, Dennewald G, et al. Pleuropulmonary changes induced by ergoline drugs. Eur Respir J 1996; 9: 1013- 9
  15. RobertM, Derbaudrenghien JP, Blampain JP, et al. Fibrotic processes associated with long-term ergotamine therapy [letter]. N Engl J Med 1984; 311: 601- 2
  16. Roth J, Ulmanova O, Ruzicka E. Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease? Cas Lek Cesk 2005; 144: 123- 6
  17. Kunkler RB, Osborn DE, Abbott RJ. Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson's disease. Br J Urol 1998; 82: 147
  18. Jimenez Jimenez FJ, Lopez Alvarez J, Sanchez-Chapado M, et al. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Clin Neuropharmacol 1995; 18: 277- 9
  19. Pierce Jr JR, Trostle DC, Warner JJ. Propranolol and retroperitoneal fibrosis. Ann Intern